登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
IBI343 in Combination Therapy for Advanced Malignant Solid Tumors
ClinicalTrials.gov 上登记的一项胃癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07483554,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Confirmed CLDN18.2 positive by central laboratory pathological tissue testing.
入选标准第 8 条
Female subjects of childbearing potential or male subjects whose partners are of childbearing potential must use effective contraception throughout the treatment period and for 6 months after the end of treatment.
入选标准第 7 条
Received treatment with a strong cytochrome P450 3A4 (CYP3A4) inhibitor within 2 weeks or 5 half-lives (whichever is longer) prior to the first dose of the investigational drug.
排除标准第 2 条
Received the last anti-tumor treatment within 4 weeks or 5 half-lives of the anti-tumor therapy (whichever is shorter) before the first dose of the investigational drug.
排除标准第 3 条
Received therapeutic or palliative radiotherapy within 2 weeks prior to the first dose of the investigational drug.
排除标准第 4 条
Underwent biliary stent placement within 7 days prior to the first dose of the investigational drug.
排除标准第 5 条
Underwent major surgery within 4 weeks prior to the first dose of the investigational drug, or has unhealed wounds, ulcers, or fractures; or plans to undergo major surgery during the study.
排除标准第 8 条
Has not recovered from toxicity caused by previous treatment to grade 0 or 1 according to NCI CTCAE v5.0 prior to the first dose of the investigational drug.
排除标准第 9 条
History of gastrointestinal perforation and/or fistula within 6 months prior to the first dose of the investigational drug that was not cured by surgical treatment.
排除标准第 10 条
An Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
入选标准第 4 条
At least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
入选标准第 2 条
Pregnant or lactating female subjects.
排除标准第 24 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;试验排除的其他疾病。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07483554,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Signed written informed consent, willing and able to comply with the protocol-specified visits and related procedures. At least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Age ≥ 18 years, no gender restrictions. An Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. Expected survival ≥ 12 weeks. Adequate bone marrow and organ function. Female subjects of childbearing potential or male subjects whose partners are of childbearing potential must use effective contraception throughout the treatment period and for 6 months after the end of treatment. Confirmed CLDN18.2 positive by central laboratory pathological tissue testing.排除标准:Exclusion Criteria:
Currently participating in another interventional clinical study, except for observational (non-interventional) clinical studies or those in the survival follow-up phase of an interventional study. Received treatment with a strong cytochrome P450 3A4 (CYP3A4) inhibitor within 2 weeks or 5 half-lives (whichever is longer) prior to the first dose of the investigational drug. Received the last anti-tumor treatment within 4 weeks or 5 half-lives of the anti-tumor therapy (whichever is shorter) before the first dose of the investigational drug. Received therapeutic or palliative radiotherapy within 2 weeks prior to the first dose of the investigational drug. Underwent biliary stent placement within 7 days prior to the first dose of the investigational drug. Planning to receive other anti-tumor treatments during the period of treatment with the investigational drug. Received any live vaccine within 4 weeks prior to the first dose of the investigational drug or planning to receive any live vaccine during the study. Underwent major surgery within 4 weeks prior to the first dose of the investigational drug, or has unhealed wounds, ulcers, or fractures; or plans to undergo major surgery during the study. Has not recovered from toxicity caused by previous treatment to grade 0 or 1 according to NCI CTCAE v5.0 prior to the first dose of the investigational drug. History of gastrointestinal perforation and/or fistula within 6 months prior to the first dose of the investigational drug that was not cured by surgical treatment. Presence of pyloric obstruction and/or persistent recurrent vomiting. Post-procedure of stent implantation in the digestive tract or trachea. Symptomatic central nervous system metastasis. Bone metastasis with risk of paraplegia. Interstitial lung disease requiring steroid treatment, or history of interstitial lung disease, non-infectious pneumonia, severe impairment of pulmonary function, or uncontrolled pulmonary disease such as pulmonary fibrosis, severe radiation pneumonitis, acute lung injury, etc., or suspected of having these diseases during the screening period. Presence of uncontrolled disease. History of other primary malignant tumors. Known history of immunodeficiency. History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation. Previous treatment with topoisomerase inhibitor-based antibody-drug conjugates. For subjects receiving drug treatment, a history of allergy to the corresponding drug or formulation. For subjects receiving drug treatment, contraindications for the corresponding drug. For subjects receiving drug treatment, a history of permanent discontinuation of the corresponding drug due to related adverse reactions. Pregnant or lactating female subjects. Other conditions deemed unsuitable for participation in this study by the investigator.
引自 ClinicalTrials.gov, NCT07483554, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07483554,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。